LifeVantage Corporation (LFVN)

Market Cap	82.26M -51.6%
Revenue (ttm)	195.32M -12.2%
Net Income	5.75M -37.1%
EPS	0.45 -35.7%
Shares Out	12.62M
PE Ratio	14.47
Forward PE	18.03
Dividend	$0.20 (3.07%)
Ex-Dividend Date	Jun 1, 2026

Volume	41,980
Open	6.59
Previous Close	6.57
Day's Range	6.40 - 6.63
52-Week Range	3.90 - 14.28
Beta	0.76
Analysts	Buy
Price Target	7.00 (+7.36%)
Earnings Date	Aug 27, 2026

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, ...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Terrence Moorehead
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Analyst Summary

According to 2 analysts, the average rating for LFVN stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 7.36% from the latest price.

Price Target

$7.0

(7.36% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 18, 2026

Data Sources Report a data error